Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Maintains Buy on Satsuma Pharmaceuticals, Lowers Price Target to $3

HC Wainwright & Co. analyst Oren Livnat maintains Satsuma Pharmaceuticals (NASDAQ:STSA) with a Buy and lowers the price target from $18 to $3.
byBenzinga Newsdesk
November 15, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

HC Wainwright & Co. analyst Oren Livnat maintains Satsuma Pharmaceuticals (NASDAQ:STSA) with a Buy and lowers the price target from $18 to $3.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

If You Invested $1,000 In Microsoft Stock When Bill Gates Left As CEO, Here’s How Much You’d Have Now

By Chris Katje
January 23, 11:51 AM
Founders of companies typically serve as the first Chief Executive Officer of their creation before someone from within the company or from the outside is brought in to lead and potentially push the business in a new direction. Investors oftentimes will invest in companies that have undergone a management change, which can lead to new focus areas and growth opportunities.

MSFT